Citations

Mayo Clinic

Showing 10 of 108602 citations.

Investigational drugs in phase II clinical trials for primary biliary cholangitis
Silveira, Marina G., Lindor, Keith D.

Expert Opinion on Investigational Drugs | August 24, 2017 | Volume: 26 | Issue: 10 | Pages: 1115-1121

10.1080/13543784.2017.1371135 | PMID 28836457 Get It

Flow Cytometric Immune Profiling in Infliximab-Associated Tuberculosis
Pennington, Kelly M. , Sasieta, Humberto C., Ramos, Guiherme P, Erskine, Courtney L. , Keulen, Virginia P. Van , Peikert, Tobias, Escalante, Patricio , Ramos, Guilherme Piovezani , Van Keulen, Virginia P, Ramos, Guilherme P

Clinical Medicine Insights: Case Reports | August 24, 2017 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/1179547617724776 | PMID 28890660 Get It

Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis. As part of a research study, we performed flow cytometric immune profiling, which has previously not been reported in patients with active tuberculosis taking tumor necrosis α antagonists. The flow cytometry results were within the positive thresholds for tuberculosis infection. Flow cytometric immune profiling may be a valid diagnostic tool for patients taking tumor necrosis factor α antagonists.
Author response: NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma
Xiao, Zhijie , Zhu, Yun , Gao, Xuyuan , Tin, Vicky Pui‐Chi, Wong, Maria Pik , Liu, Jing , Wang, Siqi , Qin, Jing , Wang, Junwen , Wong, Maria Pik

No container title available | August 24, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.26733.032 Get It

Expanded phenotype in a patient with spastic paraplegia 7
Gass, Jennifer , Blackburn, Patrick R. , Jackson, Jessica L. , Macklin, Sarah , Gerpen, Jay Van, Atwal, Paldeep S. , Jackson, Jessica, Van Gerpen, Jay, Atwal, Paldeep S , Gerpen, Jay A. van

Clinical Case Reports | August 24, 2017 | Volume: 5 | Issue: 10 | Pages: 1620-1622

10.1002/ccr3.1109 | PMID 29026558 Get It

Key Clinical MessageHereditary spastic paraplegia is a group of clinically and genetically heterogeneous neurodegenerative disorders, often characterized by weakness and spasticity in the lower limbs. In our study, we describe a spastic paraplegia type 7 patient with an expanded phenotype who was diagnosed after the discovery of pathogenic variants in SPG7.
Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry
Laurino, Mercy , Truitt, Anjali R. , Tenney, Lederle, Fisher, Douglass, Lindor, Noralane M. , Veenstra, David L. , Jarvik, Gail P. , Laurino, Mercy Y , Jarvik, Gail P , Newcomb, Polly A. , Fullerton, Stephanie M.

Molecular Genetics & Genomic Medicine | August 24, 2017 | Volume: 5 | Issue: 6 | Pages: 700-708

10.1002/mgg3.328 | PMID 29178651 Get It

AbstractBackgroundThe extent to which participants act to clinically verify research results is largely unknown. This study examined whether participants who received Lynch syndrome (LS)‐related findings pursued researchers’ recommendation to clinically verify results with testing performed by a CLIA‐certified laboratory.MethodsThe Fred Hutchinson Cancer Research Center site of the multinational Colon Cancer Family Registry offered non‐CLIA individual genetic research results to select registry participants (cases and their enrolled relatives) from 2011 to 2013. Participants who elected to receive results were counseled on the importance of verifying results at a CLIA‐certified laboratory. Twenty‐six (76.5%) of the 34 participants who received genetic results completed 2‐ and 12‐month postdisclosure surveys; 42.3% of these (11/26) participated in a semistructured follow‐up interview.ResultsWithin 12 months of result disclosure, only 4 (15.4%) of 26 participants reported having verified their results in a CLIA‐certified laboratory; of these four cases, all research and clinical results were concordant. Reasons for pursuing clinical verification included acting on the recommendation of the research team and informing future clinical care. Those who did not verify results cited lack of insurance coverage and limited perceived personal benefit of clinical verification as reasons for inaction.ConclusionThese findings suggest researchers will need to address barriers to seeking clinical verification in order to ensure that the intended benefits of returning genetic research results are realized.
The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study
Hess, Paul L. , Al‐Khalidi, Hussein R. , Mulder, Hillary , Kucharska‐Newton, Anna , Rosamond, Wayne, Curtis, Lesley H. , Prineas, Ronald J. , Sotoodehnia, Nona , Friedman, Daniel J , Rosamond, Wayne D. , Lópes, Renato D. , Gersh, Bernard J. , Mark, Daniel B. , Post, Wendy S. , Al‐Khatib, Sana M. , Kucharska-Newton, Anna M , Mulder, Hillary

Journal of the American Heart Association | August 24, 2017 | Volume: 6 | Issue: 8 | Pages: No page available

10.1161/jaha.117.006103 | PMID 28835363 Get It

Background Prior studies have demonstrated a link between the metabolic syndrome and increased risk of cardiovascular mortality. Whether the metabolic syndrome is associated with sudden cardiac death is uncertain. Methods and Results We characterized the relationship between sudden cardiac death and metabolic syndrome status among participants of the ARIC (Atherosclerosis Risk in Communities) Study (1987–2012) free of prevalent coronary heart disease or heart failure. Among 13 168 participants, 357 (2.7%) sudden cardiac deaths occurred during a median follow‐up of 23.6 years. Participants with the metabolic syndrome (n=4444) had a higher cumulative incidence of sudden cardiac death than those without it (n=8724) (4.1% versus 2.3%, P <0.001). After adjustment for participant demographics and clinical factors other than components of the metabolic syndrome, the metabolic syndrome was independently associated with sudden cardiac death (hazard ratio, 1.70, 95% confidence interval, 1.37–2.12, P <0.001). This relationship was not modified by sex (interaction P =0.10) or race (interaction P =0.62) and was mediated by the metabolic syndrome criteria components. The risk of sudden cardiac death varied according to the number of metabolic syndrome components (hazard ratio 1.31 per additional component of the metabolic syndrome, 95% confidence interval, 1.19–1.44, P <0.001). Of the 5 components, elevated blood pressure, impaired fasting glucose, and low high‐density lipoprotein were independently associated with sudden cardiac death. Conclusions We observed that the metabolic syndrome was associated with a significantly increased risk of sudden cardiac death irrespective of sex or race. The risk of sudden cardiac death was proportional to the number of metabolic syndrome components.
Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study
Raheel, Shafay , Matteson, Eric L. , Crowson, Cynthia S. , Myasoedova, Elena

Rheumatology | August 23, 2017 | Volume: 56 | Issue: 12 | Pages: 2154-2161

10.1093/rheumatology/kex352 | PMID 28968703 Get It

MRI of Native Knee Cartilage Delamination Injuries
White, Candace L. , Chauvin, Nancy A. , Waryasz, Gregory R. , March, Bradford T., Francavilla, Michael L.

American Journal of Roentgenology | August 23, 2017 | Volume: 209 | Issue: 5 | Pages: W317-W321

10.2214/ajr.16.17708 | PMID 28834442 Get It

Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival—In Most
Mıkhael, Joseph , Mikhael, Joseph R.

Journal of Clinical Oncology | August 23, 2017 | Volume: 35 | Issue: 29 | Pages: 3269-3271

10.1200/jco.2017.74.7014 | PMID 28834440 Get It